Characterization of a novel type of HIV-1 particle assembly inhibitor using a quantitative luciferase-Vpr packaging-based assay

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Gonzalez, Gaëlle ^a   DaFonseca, Sandrina ^a   Errazuriz, Elisabeth ^b   Coric, Pascale ^c   Souquet, Florence ^d   Turcaud, Serge ^d   Boulanger, Pierre ^a   Bouaziz, Serge ^c   Hong, Saw See ^a  

^a UMR 754   (France)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ALANINE; BETULIC ACID; ETHYLENEDIAMINE; GAG PROTEIN; HYBRID PROTEIN; LUCIFERASE; LYSINE; VPR PROTEIN; VPR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; CROSS LINKING; CULTURE MEDIUM; CYTOTOXICITY; DOSE RESPONSE; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; MORULA; NONHUMAN; OLIGOMERIZATION; PROTEIN EXPRESSION; VIRUS ASSEMBLY; VIRUS CHARACTERIZATION; VIRUS RELEASE; ANIMAL; ARMYWORM; CELL LINE; ELECTRON MICROSCOPY; METABOLISM; PHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; ULTRASTRUCTURE; VIRION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; CELL LINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HIV-1; MICROSCOPY, ELECTRON; SPODOPTERA; VIRION; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 80455158173     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027234     Document Type: Article

References (88)

1. Greene WC, Debyser Z, Ikeda Y, Freed EO, Stephens E, et al. (2008) Novel targets for HIV therapy. Antiviral Res 80: 251-265.
2. Wainberg MA, (2009) Perspectives on antiviral drug development. Antiviral Res 81: 1-5.
3. Dorr CR, Yemets S, Kolomitsyna O, Krasutsky P, Mansky LM, (2011) Triterpene derivatives that inhibit human immunodeficiency virus type 1 replication. Bioorg Med Chem Lett 21: 542-545.
4. Kanamoto T, Kashiwada Y, Kanbara K, Gotoh K, Yoshimori M, et al. (2001) Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation. Antimicrob Agents Chemother 45: 1225-1230.
5. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, et al. (2003) PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci USA 100: 13555-13560.
6. Li F, Zoumplis D, Matallana C, Kilgore NR, Reddick M, et al. (2006) Determinants of activity of the HIV-1 maturation inhibitor PA-457. Virology 356: 217-224.
7. Kashiwada Y, Hashimoto F, Cosentino LM, Chen CH, Garrett PE, et al. (1996) Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. J Med Chem 39: 1016-1017.
8. Zhou J, Yuan X, Dismuke D, Forshey BM, Lundquist C, et al. (2004) Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol 78: 922-929.
9. Zhou X, Parent LJ, Wills JW, Resh MD, (1994) Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol 68: 2556-2569.
10. Aiken C, Chen CH, (2005) Betulinic acid derivatives as HIV-1 antivirals. Trends Mol Med 11: 31-36.
11. Zhou J, Chen CH, Aiken C, (2004) The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid. Retrovirology 1: 15.
12. DaFonseca S, Blommaert A, Coric P, Hong SS, Bouaziz S, et al. (2007) The 3-O-(3',3'-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells. Antiviral Ther 12: 1185-1203.
13. Keller PW, Adamson CS, Heymann JB, Freed EO, Steven AC, (2011) HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice. J Virol 85: 1420-1428.
14. Adamson CS, Freed EO, (2010) Novel approaches to inhibiting HIV-1 replication. Antiviral Res 85: 119-141.
15. Muriaux D, Darlix J-L, Cimarelli A, (2004) Targeting the assembly of the human immunodeficiency virus type 1. Current Pharmaceutical Design 10: 3725-3739.
16. Shvadchak V, Sanglier S, Rocle S, Villa P, Haiech J, et al. (2009) Identification by high throughput screening of small compounds inhibiting the nucleic acid destabilization activity of the HIV-1 nucleocapsid protein. Biochimie 91: 916-923.
17. Tang C, Loeliger E, Kinde I, Kyere S, Mayo K, et al. (2003) Antiviral inhibition of the HIV-1 capsid protein. J Mol Biol 327: 1013-1020.
18. Sticht J, Humbert M, Findlow S, Bodem J, Muller B, et al. (2005) A peptide inhibitor of HIV-1 assembly in vitro. Nat Struct Mol Biol 12: 671-677.
19. Ternois F, Sticht J, Duquerroy S, Kräusslich H-G, (2005) The HIV-1 capsid potein C-terminal domain in complex with a virus assembly inhibitor. Nat Struct Mol Biol 12: 678-682.
20. Klikova M, Rhee SS, Hunter E, Ruml T, (1995) Efficient in vivo and in vitro assembly of retroviral capsids from Gag precursor proteins expressed in bacteria. J Virol 69: 1093-1098.
21. Jacobs E, Gheysen D, Thines D, Francotte M, de Wilde M, (1989) The HIV-1 Gag precursor Pr55gag synthesized in yeast is myristoylated and targeted to the plasma membrane. Gene 79: 71-81.
22. Sakuragi S, Sakuragi J, Morikawa Y, Shioda T, (2006) Development of a rapid and convenient method for the quantification of HIV-1 budding. Microbes Infect 8: 1875-1881.
23. Sakalian M, McMurtrey CP, Deeg FJ, Maloy CW, Li F, et al. (2006) 3-O-(3',3'-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro. J Virol 80: 5716-5722.
24. Wilk T, Gross I, Gowen BE, Rutten T, de Haas F, et al. (2001) Organization of immature human immunodeficiency virus type 1. J Virol 75: 759-771.
25. Carrière C, Gay B, Chazal N, Morin N, Boulanger P, (1995) Sequence requirement for encapsidation of deletion mutants and chimeras of human immunodeficiency virus type 1 Gag precursor into retrovirus-like particles. J Virol 69: 2366-2377.
26. Chazal N, Carrière C, Gay B, Boulanger P, (1994) Phenotypic characterization of insertion mutants of the human immunodeficiency virus type 1 Gag precursor expressed in recombinant baculovirus-infected cells. J Virol 68: 111-122.
27. Chazal N, Gay B, Carrière C, Tournier J, Boulanger P, (1995) Human immunodeficiency virus type 1 MAp17 deletion mutants expressed in baculovirus-infected cells: cis and trans effects on the Gag precursor assembly pathway. J Virol 69: 365-375.
28. Gay B, Tournier J, Chazal N, Carrière C, Boulanger P, (1998) Morphopoietic determinants of HIV-1 GAG particles assembled in baculovirus-infected cells. Virology 247: 160-169.
29. Gheysen D, Jacobs E, de Foresta F, Thiriart C, Francotte M, et al. (1989) Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 59: 103-112.
30. Hong SS, Boulanger P, (1993) Self-assembly-defective dominant mutants of HIV-1 Gag phenotypically expressed in baculovirus-infected cells. J Virol 67: 2787-2798.
31. Royer M, Bardy M, Gay B, Tournier J, Boulanger P, (1997) Proteolytic activity in vivo and encapsidation of recombinant HIV-1 proteinase expressed in baculovirus-infected cells. J Gen Virol 78: 131-142.
32. Royer M, Cerutti M, Gay B, Hong SS, Devauchelle G, et al. (1991) Functional domains of HIV-1 gag-polyprotein expressed in baculovirus-infected cells. Virology 184: 417-422.
33. Royer M, Hong SS, Gay B, Cerutti M, Boulanger P, (1992) Expression and extracellular release of human immunodeficiency virus type 1 Gag precursors by recombinant baculovirus-infected cells. J Virol 66: 3230-3235.
34. Cohen EA, Dehni G, Sodroski JG, Haseltine WA, (1990) Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J Virol 64: 3097-3099.
35. Kobinger GP, Borsetti A, Nie Z, Mercier J, Daniel N, et al. (1998) Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins. J Virol 5441-5448.
36. Accola MA, Höglund S, Göttlinger HG, (1998) A putative alpha-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly. J Virol 72: 2072-2078.
37. Bachand F, Yao XJ, Hrimech M, Rougeau N, Cohen EA, (1999) Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 gag precursor. J Biol Chem 274: 9083-9091.
38. Jenkins Y, Pornillos O, Rich RL, Myszka DG, Sundquist WI, et al. (2001) Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag). J Virol 75: 10537-10542.
39. Müller B, Tessmer U, Schubert U, Kräusslich H-G, (2000) Human immunodeficiency virus type 1 Vpr protein is incorporated into the virion in significantly smaller amounts than Gag and is phosphorylated in infected cells. J Virol 74: 9727-9731.
40. Mahalingam S, Khan SA, Murali R, Jabbar MA, Monken CE, et al. (1995) Mutagenesis of the putative alpha-helical domain of the Vpr protein of human immunodeficiency virus type 1: effect on stability and virion incorporation. Proc Natl Acad Sci USA 92: 3794-3798.
41. Morellet N, Bouaziz S, Petitjean P, Roques BP, (2003) NMR structure of the HIV-1 regulatory protein VPR. J Mol Biol 327: 215-227.
42. Singh SP, Tomkowicz B, Lai D, Cartas M, Mahalingam S, et al. (2000) Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr. J Virol 74: 10650-10657.
43. Yao XJ, Subbramanian RA, Rougeau N, Boisvert F, Bergeron D, et al. (1995) Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. J Virol 69: 7032-7044.
44. Accola MA, Bukovsky AA, Jones MS, Göttlinger HG, (1999) A conserved dileucine-containing motif in p6(gag) governs the particle association of Vpx and Vpr of simian immunodeficiency viruses SIV(mac) and SIV(agm). J Virol 73: 9992-9999.
45. Lu YL, Bennett RP, Wills JW, Gorelick R, Ratner L, (1995) A leucine triplet repeat sequence (LXX)4 in p6 gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J Virol 69: 6873-6879.
46. Lu YL, Spearman P, Ratner L, (1993) Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions. J Virol 67: 6542-6550.
47. Selig L, Pages J-C, Tanchou V, Prévéral S, Berlioz-Torrent C, et al. (1999) Interaction with the p6 domain of the Gag precursor mediates incorporation into virions of Vpr and Vpx proteins from primate lentiviruses. J Virol 73: 592-600.
48. Votteler J, Studtrucker N, Sörgel S, Münch J, Rücker E, et al. (2007) Proline 35 of human immunodeficiency virus type 1 (HIV-1) Vpr regulates the integrity of the N-terminal helix and the incorporation of Vpr into virus particles and supports the replication of R5-tropic HIV-1 in human lymphoid tissue ex vivo. J Virol 81: 9572-9576.
49. Mayaux J-F, Bousseau A, Pauwels R, Huet T, Henin Y, et al. (1994) Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells. Proc Natl Acad Sci USA 91: 3564-3568.
50. Soler F, Poujade C, Evers M, Carry J-C, Henin Y, et al. (1996) Betulinic acid derivatives: a new class of specific inhibitors of human immunodeficiency virus type 1 entry. J Med Chem 39: 1069-1083.
51. Lavallée C, Yao XJ, Ladha A, Göttlinger H, Haseltine WA, et al. (1994) Requirement of the Pr55gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles. J Virol 68: 1926-1934.
52. Paxton W, Connor RI, Landau NR, (1993) Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J Virol 67: 7229-7237.
53. Huvent I, Hong SS, Fournier C, Gay B, Tournier J, et al. (1998) Interaction and co-encapsidation of HIV-1 Vif and Gag recombinant proteins. J Gen Virol 79: 1069-1081.
54. DaFonseca S, Coric P, Gay B, Hong SS, Bouaziz S, et al. (2008) The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain. Virol J 5: 162.
55. Turcaud S, Chazal N, Coric P, Souquet F, Briand L, et al. (2011) Synthesis of new derivatives of Bevirimat, showing a higher activity against HIV-1 maturation. J Med Chem, submitted.
56. Adamson CS, Freed EO, (2007) Human immunodeficiency virus type 1 assembly, release and maturation. Adv Pharmacol 55: 347-387.
57. Adamson CS, Jones IM, (2004) The molecular basis of HIV capsid assembly- five years of progress. Rev Med Virol 14: 107-121.
58. Cimarelli A, Darlix J-L, (2002) Assembling the human immunodeficiency virus type 1. Cell Mol Life Sci 59: 1166-1184.
59. Swanson CM, Puffer BA, Ahmad KM, Doms RW, Malim MH, (2004) Retroviral mRNA nuclear export elements regulate protein function and virion assembly. EMBO J 23: 2632-2640.
60. Wang CT, Stegeman-Olsen J, Zhang Y, Barklis E, (1994) Assembly of HIV GAG-B-galactosidase fusion proteins into virus particles. Virology 200: 524-534.
61. Larson DR, Johnson MC, Webb WW, Vogt VM, (2005) Visualization of retrovirus budding with correlated light and electron microscopy. Proc Natl Acad Sci USA 102: 15453-15458.
62. Perrin-Tricaud C, Davoust J, Jones IM, (1999) Tagging the human immunodeficiency virus gag protein with green fluorescent protein. Minimal evidence for colocalisation with actin. Virology 255: 20-25.
63. Alfadhli A, Dhenub TC, Still A, Barklis E, (2005) Analysis of human immunodeficiency virus type 1 Gag dimerization-induced assembly. J Virol 79: 14498-14506.
64. Fritz JV, Dujardin D, Godet J, Didier P, De Mey J, et al. (2010) HIV-1 Vpr oligomerization and not that of Gag directs the interaction between Vpr and Gag. J Virol 84: 1585-1596.
65. Le Rouzic E, Benichou S, (2005) The Vpr protein from HIV-1: distinct roles along the viral life cycle. Retrovirology 2: 11.
66. Aguiar RS, Lovsin N, Tanuri A, Peterlin BM, (2008) Vpr.A3A chimera inhibits HIV replication. J Biol Chem 283: 2518-2525.
67. Wu X, Liu H, Xiao H, Kim J, Seshaiah P, et al. (1995) Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx. J Virol 69: 3389-3398.
68. Yao XJ, Kobinger G, Dandache S, Rougeau N, Cohen E, (1999) HIV-1 Vpr-chloramphenicol acetyltransferase fusion proteins: sequence requirement for virion incorporation and analysis of antiviral effect. Gene Ther 6: 1590-1599.
69. Cavrois M, De Noronha C, Greene WC, (2002) A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol 20: 1151-1154.
70. Briggs JA, Johnson MC, Simon MN, Fuller SD, Vogt VM, (2006) Cryo-electron microscopy reveals conserved and divergent features of gag packing in immature particles of Rous sarcoma virus and human immunodeficiency virus. J Mol Biol 355: 157-168.
71. Briggs JA, Simon MN, Gross I, Kräusslich H-G, Fuller SD, et al. (2004) The stoichiometry of Gag protein in HIV-1. Nat Struct Mol Biol 11: 672-675.
72. Fender P, Ruigrok RW, Gout E, Buffet S, Chroboczek J, (1997) Adenovirus dodecahedron, a new vector for human gene transfer. Nat Biotechnol 15: 52-56.
73. Fender P, Schoehn G, Foucaud-Gamen J, Gout E, Garcel A, et al. (2003) Adenovirus dodecahedron allows large multimeric protein transduction in human cells. J Virol 77: 4960-4964.
74. Fender P, Schoehn G, Perron-Sierra F, Tucker GC, Lortat-Jacob H, (2008) Adenovirus dodecahedron cell attachment and entry are mediated by heparan sulfate and integrins and vary along the cell cycle. Virology 371: 155-164.
75. Tan M, Huang P, Xia M, Fang P-A, Zhong W, et al. (2011) Norovirus P particle, a novel platform for vaccine development and antibody production. J Virol 85: 753-764.
76. Muriaux D, Mirro J, Harvin D, Rein A, (2001) RNA is a structural element in retrovirus particles. Proc Natl Acad Sci USA 98: 5246-5251.
77. Adamson CS, Ablan SD, Boeras I, Goila-Gaur R, Soheilian F, et al. (2006) In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J Virol 80: 10957-10971.
78. Adamson CS, Waki K, Ablan SD, Salzwedel K, Freed EO, (2009) Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457). J Virol 83: 4884-4894.
79. de Marco A, Müller B, Glass B, Riches JD, Kräusslich H-G, et al. (2010) Structural analysis of HIV-1 maturation using cryo-electron tomography. PLoS Pathog 6 (11): e1001215 6 e1001215.
80. Morellet N, Druillennec S, Lenoir C, Bouaziz S, Roques BP, (2005) Helical structure determined by NMR of the HIV-1 (345-392)Gag sequence, surrounding p2: implications for particle assembly and RNA packaging. Protein Sci 14: 375-386.
81. Labrosse B, Pleskoff O, Sol N, Jones C, Henin Y, et al. (1997) Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41. J Virol 71: 8230-8236.
82. Yuan X, Huang L, Ho P, Labranche C, Chen CH, (2004) Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564. Virology 324: 525-530.
83. Jeong HJ, Chai HB, Park SY, Kim DS, (1999) Preparation of amino acid conjugates of betulinic acid with activity against human melanoma. Bioorg Med Chem Lett 9: 1201-1204.
84. Yao XJ, Rougeau N, Duisit G, Lemay J, Cohen EA, (2004) Analysis of HIV-1 Vpr determinants responsible for cell growth arrest in Saccharomyces cerevisiae. Retrovirology 1: 21.
85. Hong SS, Karayan L, Tournier J, Curiel DT, Boulanger PA, (1997) Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J 16: 2294-2306.
86. Mosmann T, (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
87. Peytavi R, Hong SS, Gay B, Dupuy d'Angeac A, Selig L, et al. (1999) H-EED, the product of the human homolog of the murine eed gene, binds to the matrix protein of HIV-1. J Biol Chem 274: 1635-1645.
88. Knoller S, Shpungin S, Pick E, (1991) The membrane-associated component of the amphiphile-activated, cytosol-dependent superoxide-forming NADPH oxidase of macrophages is identical to cytochrome b559. J Biol Chem 266: 2795-2804.